Literature DB >> 28186436

Drug delivery to the eye: what benefits do nanocarriers offer?

Rini Rachel Joseph1, Subbu S Venkatraman1,2.   

Abstract

Ocular drug delivery has seen several advances in the past few decades, with respect to new drugs, improved formulations, targeted delivery, as well as exploration of new routes of drug administration. New materials have been explored for encasing existing drugs, which can enhance treatment by increasing bioavailability, decreasing toxicity, providing better tissue adherence, targeted delivery as well as increased duration of action. The challenges and requirements are different for the anterior and posterior ocular segments. This review summarizes the recent advances in sustained ocular therapy, both to the anterior and posterior segments, which have been made possible, thanks to nanotechnology. We also discuss the distribution and fate of these nanocarriers themselves, postadministration, as well as clearance from ocular tissues.

Entities:  

Keywords:  anterior segment delivery; fate and ocular disposition; liposomes; nanoparticles; posterior segment delivery; sustained delivery

Mesh:

Substances:

Year:  2017        PMID: 28186436     DOI: 10.2217/nnm-2016-0379

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  37 in total

Review 1.  Challenges and opportunities for drug delivery to the posterior of the eye.

Authors:  Fernando J Cabrera; Daniel C Wang; Kartik Reddy; Ghanashyam Acharya; Crystal S Shin
Journal:  Drug Discov Today       Date:  2019-06-05       Impact factor: 7.851

2.  Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells.

Authors:  Vibhuti Agrahari; Guorong Li; Vivek Agrahari; Iris Navarro; Kristin Perkumas; Abhirup Mandal; W Daniel Stamer; Ashim K Mitra
Journal:  Nanomedicine (Lond)       Date:  2017-07-31       Impact factor: 5.307

3.  Dendrimers for Ocular Drug Delivery.

Authors:  Michael G Lancina; Hu Yang
Journal:  Can J Chem       Date:  2017-05-11       Impact factor: 1.118

Review 4.  Nanotechnology in retinal drug delivery.

Authors:  Sibo Jiang; Yesenia L Franco; Yan Zhou; Jianjun Chen
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

5.  Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Authors:  Jayoung Kim; Raquel Lima E Silva; Ron B Shmueli; Adam C Mirando; Stephany Y Tzeng; Niranjan B Pandey; Elana Ben-Akiva; Aleksander S Popel; Peter A Campochiaro; Jordan J Green
Journal:  Acta Biomater       Date:  2019-07-30       Impact factor: 8.947

Review 6.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

7.  The humanin peptide mediates ELP nanoassembly and protects human retinal pigment epithelial cells from oxidative stress.

Authors:  Zhe Li; Parameswaran G Sreekumar; Santosh Peddi; David R Hinton; Ram Kannan; John Andrew MacKay
Journal:  Nanomedicine       Date:  2019-10-23       Impact factor: 5.307

Review 8.  Principles of pharmacology in the eye.

Authors:  Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood
Journal:  Br J Pharmacol       Date:  2017-10-10       Impact factor: 8.739

Review 9.  Gene Therapy in the Anterior Eye Segment.

Authors:  Cynthia Amador; Ruchi Shah; Sean Ghiam; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.391

10.  Ophthalmic delivery of hydrophilic drugs through drug-loaded oleogels.

Authors:  Russell Macoon; Anuj Chauhan
Journal:  Eur J Pharm Sci       Date:  2020-11-01       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.